BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

NCT00727506 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma

Interventions

DRUG: BIBW 2992
DRUG: TMZ
DRUG: BIBW 2992 plus TMZ

Sponsor

Boehringer Ingelheim